Illumina accused of fraud in DNA tech patents dispute

12-01-2021

Muireann Bolger

Illumina accused of fraud in DNA tech patents dispute

Michael Vi / Shutterstock.com

Illumina tried to secure its control over the DNA sequencing technology market by violating antitrust law, according to a suit by BGI Americas and two of its subsidiaries, at the US Court for the District Court of San Francisco.


Illumina, DNA, BGI, US Patent and Trademark Office, antitrust violations, China

LSIPR